Neuberger Berman Group
HRTX icon

Neuberger Berman Group’s Heron Therapeutics HRTX Stock Holding History

Neuberger Berman Group’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.6K Buy
+38,987
New +$31.3K ﹤0.01% 2327
2018
Q3 		– Sell
-26,500
Closed -$1.03M – 1654
2018
Q2 		$1.03M Buy
+26,500
New +$844K ﹤0.01% 1224

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Neuberger Berman Group's HRTX Position: Q2 2026 in Review

Neuberger Berman Group opened a new position in Heron Therapeutics (HRTX) in Q2 2026: 38,987 shares worth $16.6K. The stake represents ﹤0.01% of the portfolio and ranks #2327 among its holdings. This is a return to the name: Neuberger Berman Group previously reported a position in HRTX as recently as Q2 2018.

Neuberger Berman Group first reported a position in HRTX in Q2 2018 and has held it in 2 quarters since. The position peaked at $1.03M in Q2 2018. 163 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • Neuberger Berman Group held 38,987 shares of Heron Therapeutics worth $16.6K as of Q2 2026.
  • Heron Therapeutics was a new Neuberger Berman Group position in Q2 2026.
  • Heron Therapeutics made up ﹤0.01% of Neuberger Berman Group's portfolio in Q2 2026, its #2327 holding.
  • Neuberger Berman Group first reported a position in Heron Therapeutics in Q2 2018 and has held it in 2 quarters since.
  • Neuberger Berman Group's Heron Therapeutics position peaked at $1.03M in Q2 2018.
  • 163 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on Neuberger Berman Group's 13F filing for Q2 2026, filed 13 Aug 2026.